Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE We report the case of a 51-year-old woman admitted to the acute medical unit with abdominal pain and vomiting, who was diagnosed with euglycaemic diabetic ketoacidosis secondary to recent initiation of an SGLT2-i medication (dapagliflozin). 31537607 2019
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE Euglycemic diabetic ketoacidosis (DKA) is a known complication of sodium-glucose co-transporter 2 (SGLT-2) inhibitors that have been reported in the literature. 31489272 2019
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE We performed a literature review of this topic and discuss the pathophysiology, diagnosis, management, and prevention of SGLT2-inhibitor-induced euDKA. 31218148 2019
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE : The increasing utilization of SGLT2 inhibitor in patients with type 2 diabetes mellitus will inevitably lead to more cases of eDKA seen in the ED. 31027990 2019
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE Sodium glucose cotransporter 2 inhibitors are currently widely used antihyperglycaemic medications that are considered to be associated with euglycaemic diabetic ketoacidosis. 30968118 2019
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE This report highlights the importance of recognizing EDKA as a complication of oral anti-diabetics and discontinuing SGLT-2 inhibitors days prior to surgery and ICU admission. 31259114 2019
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 GeneticVariation disease BEFREE Both drug classes are associated with the rare but serious life-threatening complications that result from metabolic acidosis, including lactic acidosis (with metformin) and euglycemic diabetic ketoacidosis (with SGLT2 inhibitors). 30639796 2019
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE The SGLT-2 inhibitor-associated EDKA also indicates a necessary review of our previous understanding of "diabetic" ketoacidosis, since the SGLT-2 inhibitor predisposes patients to DKA in a "starvation" way. 30369948 2018
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant. 29602453 2018
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE Euglycemic diabetic ketoacidosis (eDKA) is however challenging to identify in the emergency department (ED) due to absence of marked hyperglycemia, often leading to delayed diagnosis and treatment. eDKA has been recently found to be associated with sodium-glucose cotransporter 2 (SGLT2) inhibitors, one of the newest classes of antidiabetics, though there are very limited reports implicating dapagliflozin as the offending agent in ED patients. 29923997 2018
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE Sodium glucose cotransporter 2 inhibitors have increased risk of urogenital infections and possible risk of "euglycaemic" diabetic ketoacidosis. 29320602 2018
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE Areas covered: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been linked with the scarce, but serious, complication of euglycemic diabetic ketoacidosis, as well as with an increase in serum potassium, magnesium and phosphorus levels. 28748724 2017
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 GeneticVariation disease BEFREE Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. 27717592 2017
CUI: C4524093
Disease: Euglycaemic diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
0.100 Biomarker disease BEFREE In rare cases, SGLT2 inhibitors administration may be followed by euglycemic diabetic ketoacidosis. 27819144 2017